ECM
TPST icon

Element Capital Management’s Tempest Therapeutics TPST Stock Holding History

Element Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5
Closed -$21K – 162
2017
Q3 		$21K Sell
5
-44
-90% -$188K 0.01% 63
2017
Q2 		$225K Buy
+49
New +$207K 0.05% 94

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Element Capital Management's TPST Position: Q4 2017 in Review

Element Capital Management sold out of Tempest Therapeutics (TPST) in Q4 2017, closing a stake of 5 shares — an estimated $21K sold.

Element Capital Management first reported a position in TPST in Q2 2017 and held it in 2 quarters. The position peaked at $225K in Q2 2017. 50 funds tracked by Wall St. Rank hold TPST as of Q4 2017.

  • Element Capital Management reported no remaining Tempest Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Element Capital Management sold 5 Tempest Therapeutics shares in Q4 2017, an estimated $21K.
  • Element Capital Management first reported a position in Tempest Therapeutics in Q2 2017 and held it in 2 quarters.
  • Element Capital Management's Tempest Therapeutics position peaked at $225K in Q2 2017.
  • 50 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2017.

Based on Element Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.